Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexmedetomidine for Hemodynamic Response in CABG
NCT06238011Not yet recruiting
- Sponsor
- Sawanpracharak Hospital
- Start
- Feb 2024
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of dexmedetomidine in coronary artery disease (CAD) (2 arms), sponsored by Sawanpracharak Hospital. Primary endpoints: Heart Rate and Systolic, Diastolic, and Mean Blood Pressure. Planned start Feb 2024; status: not yet recruiting.
02
Drugs
dexmedetomidine
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT06238011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06238011.